Osimertinib compared to docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small cell lung cancer.

被引：2
|
作者：
Nie, Keke
Zhang, Zhongfa
Zou, Xiao
Zhang, Chunling
Zhuang, Xingjun
Yu, Zhuang
Lan, Ketao
Ji, Youxin
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9017
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer
    Nie, Keke
    Zhang, Zhongfa
    Zhang, Chunling
    Geng, Chuanxin
    Zhang, Ling
    Xu, Xiajuan
    Liu, Shichao
    Wang, Songping
    Zhuang, Xingjun
    Lan, Ketao
    Ji, Youxin
    LUNG CANCER, 2018, 121 : 5 - 11
  • [2] Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China
    Rui, Mingjun
    Li, Hongchao
    CLINICAL THERAPEUTICS, 2020, 42 (11) : 2159 - +
  • [3] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Sha Liu
    Tao Pan
    Ming-Kun Wang
    Jie Wang
    Shuang Zhang
    Ping Zhou
    Clinical Drug Investigation, 2022, 42 : 459 - 464
  • [4] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Liu, Sha
    Pan, Tao
    Wang, Ming-Kun
    Wang, Jie
    Zhang, Shuang
    Zhou, Ping
    CLINICAL DRUG INVESTIGATION, 2022, 42 (05) : 459 - 464
  • [5] Genomic Profiling of EGFR T790M Mutated Non-Small Cell Lung Cancer to Evaluate the Mechanisms of Resistance to Osimertinib
    Puri, S.
    Hicks, J.
    Knepper, T.
    Smith, M.
    Boyle, T.
    Gray, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1848 - S1849
  • [6] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [7] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [8] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [9] Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
    Chalmers, Anna
    Jensen, Leif
    Akerley, Wallace
    LUNG CANCER, 2017, 114 : 68 - 69
  • [10] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
    Arulananda, Surein
    Do, Hongdo
    Musafer, Ashan
    Mitchell, Paul
    Dobrovic, Alexander
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1728 - 1732
12345